RxSight, Inc. (NASDAQ:RXST) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund increased its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 38.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 407,035 shares of the company's stock after buying an additional 112,984 shares during the quarter. New York State Common Retirement Fund owned 1.00% of RxSight worth $10,278,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of RXST. Royal Bank of Canada grew its stake in RxSight by 3,094.6% during the fourth quarter. Royal Bank of Canada now owns 508,491 shares of the company's stock worth $17,481,000 after purchasing an additional 492,574 shares during the period. DF Dent & Co. Inc. acquired a new stake in RxSight during the fourth quarter worth approximately $14,524,000. Bank of America Corp DE grew its stake in RxSight by 23.7% during the fourth quarter. Bank of America Corp DE now owns 2,159,923 shares of the company's stock worth $74,258,000 after purchasing an additional 413,737 shares during the period. Artisan Partners Limited Partnership grew its stake in RxSight by 32.6% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock worth $53,345,000 after purchasing an additional 381,389 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in RxSight by 196.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 359,144 shares of the company's stock worth $12,346,000 after purchasing an additional 237,877 shares during the period. 78.78% of the stock is currently owned by institutional investors.

RxSight Stock Down 0.4%

Shares of RxSight stock traded down $0.03 on Friday, reaching $7.35. The company's stock had a trading volume of 1,249,176 shares, compared to its average volume of 819,912. RxSight, Inc. has a 52-week low of $6.32 and a 52-week high of $58.23. The company has a market capitalization of $298.68 million, a P/E ratio of -10.97 and a beta of 1.21. The stock has a 50-day moving average price of $13.32 and a 200-day moving average price of $21.00.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). RxSight had a negative return on equity of 9.54% and a negative net margin of 17.90%. The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $38.74 million. During the same quarter in the prior year, the company posted ($0.25) EPS. The company's quarterly revenue was up 28.5% on a year-over-year basis. Sell-side analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Oppenheimer lowered RxSight from an "outperform" rating to a "market perform" rating in a report on Wednesday, July 9th. Stifel Nicolaus dropped their target price on RxSight from $17.00 to $9.00 and set a "hold" rating on the stock in a report on Wednesday, July 9th. Jefferies Financial Group restated a "hold" rating and issued a $9.00 target price (down previously from $24.00) on shares of RxSight in a report on Thursday, July 10th. JPMorgan Chase & Co. restated an "underweight" rating and issued a $17.00 target price (down previously from $40.00) on shares of RxSight in a report on Friday, April 4th. Finally, BTIG Research restated a "neutral" rating on shares of RxSight in a report on Wednesday, July 9th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. According to MarketBeat, RxSight currently has a consensus rating of "Hold" and a consensus price target of $17.50.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.